Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

Cancer

Volumn 104, Issue 10, 2005, Pages 2141-2148

  Berenson, James B ^a   Jagannath, Sundar ^b   Barlogie, Bart ^c   Siegel, David T ^d   Alexanian, Raymond ^e   Richardson, Paul G ^f   Irwin, David ^g   Alsina, Melissa ^h   Rajkumar, S Vincent ⁱ   Srkalovic, Gordon ^j   Singhal, Seema ^j   Limenitani, Steven ^k   Niesvizky, Ruben ^l   Esseltine, Dixie L ^m   Trehu, Elizabeth ^m   Schenkein, David P ^a   Anderson, Kenneth ^f  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g Alta Bates Cancer Center   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ MAYO CLINIC   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k Carolinas Hematology Oncology Associates   (United States)

^l WEILL CORNELL MEDICAL COLLEGE   (United States)

^m MILLENNIUM PHARMACEUTICALS INC   (United States)

more..

Author keywords

Bortezomib; CREST; Extension; Myelomas; Proteasome; SUMMIT

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; PROTEASOME INHIBITOR;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ATRIOVENTRICULAR BLOCK; CARDIOMEGALY; CLINICAL TRIAL; COUGHING; DEEP VEIN THROMBOSIS; DEHYDRATION; DIZZINESS; DRUG SAFETY; ERYTHEMA; EYE IRRITATION; EYE PAIN; FATIGUE; FEMALE; FEVER; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; HYPOPROTEINEMIA; INSOMNIA; LIMB PAIN; LONG TERM CARE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; RIGOR; SEIZURE; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; SYNDROME CREST; THORAX PAIN; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PYRAZINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 27644510071     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21427     Document Type: Article

References (5)

1. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
2. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165-172.
3. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
4. Richardson PG, Sonneveld P, Schusler MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498.
5. Fitzgerald M, Fraser C, Webb I, Schenkein D, Esseltine D, Weich N. Normal hematopoietic stem cell function in mice following treatment with bortezomib. Biol Blood Marrow Transplant. 2003;9:193.